Biotech💯.Day-trader. 16 years experience. Long/Short/Options. Always look for +\- perspectives in Biotech. Not Investment Advice.Catalyst Trades Focus 🚀🚀🚀.
New York, NY
Joined April 2020
- Tweets3.9K
- Following406
- Followers1.5K
- Likes8K
BioPulse retweeted
$PFE dropped Metsera alleged oral GLP1. Also dropped GIP peptide ..
Now no talk about single amylin trial data.
Amylin and GLP1 data “ just for PK and safety “
Essentially the Metsera platform that Pfizer M&A head Andrew Baun talked about trickled to one semaglutide efficacy GLP1. That might be given monthly .. we don’t know how popular any monthly will be given irreversibility of clinical effects .. bad or good.
And how much Pfizer will generate from 12 shorts per year ?
$AMGN has its issues with monthly MariTide not the least is viscous 2.5 ML solution that pt has to inject.
After all obesity not as crowded as $JNJ CEO believes ?
Waw …since when $PFE needs help for funding its clinical trials. ? And giving out some milestones and loyalties 😂
Why not cutting the dividend?
Bourla likely does not have confidence in this GLP1 asset ?
You do not compete in the biggest market against the trillion $ leader $LLY with a subpar asset that is barely competitive with $NVO sema ?
Trying to save a few billions on acquisition.. and then u get stuck with billions in trials cost..
BioPulse retweeted
$PRAX
Raymond James is very bullish- 945 PT.
Raymond James reiterated $PRAX Strong Buy-$945 and said--We continue to view Praxis as one of the most compelling setups in SMID biotech, with the next few months offering multiple opportunities to unlock the value of what we believe could become two multi-billion-dollar CNS franchises.
[DRUG JAZZ RAPP SAGE UCBJY ESAIY OVID XENE]
Our deep dive (link) into relu's mechanism, breadth of preclinical evidence, and EMERALD's heterogeneity risk leaves us constructive on both the probability of Ph3 success and the magnitude of its commercial opportunity.
Separately, our due diligence (link) on ulixa's clinical and regulatory package, including its statistical considerations and regulatory precedent, underpins our high conviction in approval at the January 29 PDUFA.
We are encouraged by management's commercial readiness, with relu's commercial organization fully hired and ulixa's field-force buildout progressing ahead of potential launches.
Taken together, we believe Praxis is approaching a transformational stretch, with a catalyst-rich outlook, substantial commercial upside, and a balance sheet that positions the company to execute from a position of strength.
BioPulse retweeted
Chop chop BP , no time to waste
My take on BP moves:
$jnj : $cogt , $dftx , $ptgx
$lly: $abvx , $mane , $celc , $prax
$mrk: $lqda, $rvmd
$sny: $pcvx , $insm
$abbv: $xene , $prax , $abvx , $vktx
$azn: $cgon , $rytm, $insm, $abvx
$nvs: $cytk , $srrk , $vrdn
$Rhhby: $iron , $vera, $cccc
$pfe: $celc , $cogt , $arct
$bms: $elvn , $cldx
$gsk: $cldx, $amlx , $cccc
$nvo: $gpcr, $ewtx , $rytm
BioPulse retweeted
$NRIX Piper PT $35 $1.1B in cash (end 3Q), NRIX
enterprise value is~$1B in value. current PT is unchanged since did not have
SAR448272 in our valuation model. There's valuation support from NRIX's bexobrutideg
(partnered with Roche) which is in Ph3 trials in CLL and potential advancement of Ph2
development in autoimmune indications. Bexobrutideg offers potential differentiation
compared to other BTK degraders in development.
$NRIX to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition globenewswire.com/news-relea…
$MLYS - I’ve been wrong on this but one to watch tomorrow. Close to that 30 day run-up window. Long over PMH. Will add a decent spot if that happens.
$MLYS anyone listen to call ?? Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 –
– New analyses from the pivotal Launch-HTN trial showed 46% of participants with uncontrolled or resistant hypertension receiving lorundrostat 50 mg achieved the AHA/ACC guideline systolic blood pressure target of <130 mmHg at Week 12 –
– Transform-HTN open-label extension trial data selected for late-breaking presentation at American Heart Association Scientific Sessions 2026 –
– Conference call today at 4:30 p.m. ET –
3
602
BioPulse retweeted
$MLYS buying opportunity??
CV drugs are always slow to ramp.
Entresto had a very slow start (<$20M for first 3 quarters after launch) and eventually made $7.8B in peak sales
$NRIX nice late curl. Always watch the bounce from the first green 3 min or 10 min candle on these.
$NRIX $XBI
What $16.50 implies:
👉About 109M shares at $16.50 is a market cap of about $1.8B, down from about $2.8B.
👉Cash is about $1.1B, or roughly $10 a share. That leaves an enterprise value of about $0.7B, or about $6.50 a share, for everything else.
👉Everything else includes Nurix's half of US profits on bexobrutideg, ex-US royalties from the low to high teens, up to $1.6B in Roche milestones, the Gilead and Pfizer deals, the second Sanofi program, NX-1607 and the platform.
👉For comparison, Roche paid $700M upfront for its own share of bexobrutideg alone. At $0.7B of enterprise value, the market is roughly saying Nurix's retained share of its lead Phase 3 drug, plus all the other programs, is worth what Roche just paid for the other half. Don't read that too literally, though. The $0.7B is net of the 40% development cost share and the cash burn Nurix still faces before launch.
Opportunity the $XBI gives when it’s in this mode. Gift.
399
BioPulse retweeted
$NRIX disclosed that $SNY will end its Phase 1 study of oral STAT6 degrader SAR448272 and stop the initiative, removing prospective commercial milestones and royalty revenues from the candidate. Additional Sanofi-partnered efforts remain active for milestone payouts, while Nurix preserves $1.1 billion in reserves to fund operational runway into H2 2029.
$KTTA $BIVI $CAPR $KPTI $RMTI $PMN $ALZN $ATHE $JAGX $CYCN
For more biotech updates, join us on 🔗 BioPharmCatalyst 📰 Articles section
BioPulse retweeted
$NRIX I think we see multiple analyst defenses tomorrow. Looking for 20+. A discontinuation of a phase 1 study of one of multiple drugs actually saves money 😂
BioPulse retweeted
long $NRIX at 17, if you were buying this for the STAT6 program and not the NX5948 degrader then idk what to tell you - massive over reaction imo
$NRIX Nurix Therapeutics: Sanofi Discontinues Phase 1 Trial of STAT6 Degrader SAR448272, Terminates Development Program
⠀
• Discontinuation: Sanofi ends the Phase 1 trial and terminates the SAR448272 development program.
• Financial Impact: Nurix no longer expects future milestone payments or royalties from SAR448272.
• Cash Runway: Unchanged, with $1.1B in cash and investments expected to fund operations into H2 2029.
• Pipeline: Roche-partnered bexobrutideg remains in Phase 3, while NX-1607 and Gilead-partnered GS-6791 continue clinical development.
$NRIX $XBI
What $16.50 implies:
👉About 109M shares at $16.50 is a market cap of about $1.8B, down from about $2.8B.
👉Cash is about $1.1B, or roughly $10 a share. That leaves an enterprise value of about $0.7B, or about $6.50 a share, for everything else.
👉Everything else includes Nurix's half of US profits on bexobrutideg, ex-US royalties from the low to high teens, up to $1.6B in Roche milestones, the Gilead and Pfizer deals, the second Sanofi program, NX-1607 and the platform.
👉For comparison, Roche paid $700M upfront for its own share of bexobrutideg alone. At $0.7B of enterprise value, the market is roughly saying Nurix's retained share of its lead Phase 3 drug, plus all the other programs, is worth what Roche just paid for the other half. Don't read that too literally, though. The $0.7B is net of the 40% development cost share and the cash burn Nurix still faces before launch.
Opportunity the $XBI gives when it’s in this mode. Gift.